Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Top 3 Drivers in Global Gonorrhea Therapeutics Market | Technavio

Technavio Research
Posted on: 09 Nov 17

Technavio market research analysts forecast the global gonorrhea therapeutics market to grow at a CAGR of almost 3% during the forecast period, according to their latest report.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171109006393/en/

Technavio has published a new report on the global gonorrhea therapeutics market from 2017-2021. (Graphic: Business Wire)

The report further segments the global gonorrhea therapeutics market by application (functional beverages, functional food, dietary supplements, and others) and by geography (the Americas, APAC, and EMEA).

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

Technavio analysts highlight the following three market drivers that are contributing to the growth of the global gonorrhea therapeutics market:

  • Rising prevalence of disease
  • High-risk complications associated with gonorrhea
  • Growing use of new diagnostic tests

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

Rising prevalence of disease

A major health concern across the globe is the rising prevalence of gonorrhea. In the US, according to the CDC, around 700,000 new cases of gonorrhea are detected each year. The disease is the most common STD in the US after chlamydial infection. Several factors such as growing awareness, increased healthcare access, availability of diagnostic tests, resistance patterns, reporting practices, and the financial restrictions that limit the capacities of public healthcare officials to determine the disease pattern precisely have led to rising prevalence rate of gonorrhea.

According to Sapna Jha, a lead analyst at Technavio for infectious and rare diseases research, “Previously, it was most likely for men to be affected by gonorrhea when compared to women. Nevertheless, since 1996, there has been a change in this trend in prevalence rate and it has remained the same since then. The prevalence rate of gonorrhea was higher in women when compared to men in 2009.”

High-risk complications associated with gonorrhea

Gonorrhea is caused by a bacterium Neisseria gonorrhoeae (Gc) and it is a highly prevalent STD. The infection contributes to a significant number of morbidity and mortality rates. The infection can progress to the upper reproductive tract causing pelvic inflammatory disease (PID), ectopic pregnancy, chronic pain, and infertility, if left untreated. One out of five untreated women could develop PID because of the asymptomatic nature of the lower genital tract gonorrheal infection.

During pregnancy, gonorrhea causes chorioamnionitis, which is further complicated by septic abortion in 13% of women, premature or before time rupture of biological membranes in 29% of women, and preterm delivery in 23% of women. Patients are advised to seek treatment as early as possible because of the high rates of complications associated with gonorrhea.

Growing use of new diagnostic tests

There has been a growing use of newly available diagnostic tests such as nucleic acid amplification tests (NAATs) in the global gonorrhea therapeutics market. This has substantially contributed to the incidence rate of gonorrhea. To avoid the spread of the infection to the upper genital tract, diagnostic screening is an essential step as gonorrhea is often asymptomatic in nature, specifically in women.

“Pregnant women who are suspected of having the gonorrheal infection or are residing in an area where gonorrhea is prevalent are advised by the NIH to undertake a prenatal test for gonorrhea. Those who are tested positive for gonorrhea are advised to take the appropriate antibiotics for their treatment and should repeat the test after three to six months,” says Sapna.

Browse Related Reports:

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109006393/en/

Business Wire
www.businesswire.com

Last updated on: 09/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.